ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Nationwide Children’s Hospital, a research hospital specializing in gene therapy, has launched a for-profit biotechnology subsidiary called Andelyn Biosciences. Scheduled to begin commercial-scale production at a new facility in 2023, Andelyn will manufacture gene therapy products for the pharmaceutical industry. Nationwide already offers production for clinical trials and says commercial capacity is needed as more gene therapies are developed in the coming years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X